Lipitor, Atorvastatin
Lipitor, Atorvastatin Newswire (Page 5)

Lipitor, Atorvastatin Newswire (Page 5)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 5)

Results 81 - 100 of 2,379 in Lipitor, Atorvastatin (generic)

  1. Statins benefit patients undergoing major lung resection, lower major complicationsRead the original story w/Photo

    Jun 23, 2015 | Medical News

    The results of a prospective, randomized, placebo-controlled, double-blind trial of patients undergoing elective pulmonary resection was designed to evaluate the effects of statin therapy. Unfortunately, because of difficulties in enrolling patients who had never taken statins, the study was terminated early, and the sample size was smaller than anticipate.

    Comment?

  2. New study predicts outcomes of CV patients using polypill interventionRead the original story w/Photo

    Jun 19, 2015 | Medical News

    Study Published In BMJ Open Demonstrates that a 20% Improvement In Treatment Adherence With Cardiovascular Polypill, Prevents Up to 15% More Secondary CV Events A new study published in the journal BMJ Open has demonstrated that the improved treatment adherence achievable using a fixed-dose combination polypill to prevent recurring myocardial infarction, can avoid up to 15% more fatal and non-fatal CV events, conferring potential savings to healthcare systems. Cardiovascular disease is the number one cause of death worldwide and it is estimated to kill about 23.3 million people per year by 2020.

    Comment?

  3. New Cost Effectiveness Model Underlines Scope of Polypill Strategy to ...Read the original story

    Jun 19, 2015 | Sys-Con Media

    Study Published In BMJ Open Demonstrates that a 20% Improvement In Treatment Adherence With Cardiovascular Polypill, Prevents Up to 15% More Secondary CV Events )[1] has demonstrated that the improved treatment adherence achievable using a fixed-dose combination polypill to prevent recurring myocardial infarction, can avoid up to 15% more fatal and non-fatal CV events, conferring potential savings to healthcare systems.

    Comment?

  4. Tax avoidance inquiry calls on nine 'big pharma' bosses to explain tax contributionRead the original story w/Photo

    Jun 18, 2015 | Sydney Morning Herald

    Representatives from Pfizer, Johnson & Johnson, GlaxoSmithKline, Roche, Novartis, AstraZeneca, Sanofi, Eli Lilly, and Merck Sharp & Dohne have all been requested to appear before the Senate inquiry. The bosses of nine of Australia's largest multinational pharmaceutical companies will appear in front of a Senate committee investigating corporate tax avoidance.

    Comment?

  5. Amgen, Regeneron LDL-Lowering Drugs Provide Major Upside Potential To Their StocksRead the original story w/Photo

    Nov 1, 2013 | Seeking Alpha

    Wall Street is mildly optimistic about them, but appears to be withholding judgment until clinical outcomes are proven to be helped by these biologic agents. This article reviews some of what is known about the history of lowering LDL levels with drugs and finds the Street could well be overly cautious.

    Comment?

  6. AXON, REGN, BURL, FIVE: Jim Cramer's ViewsRead the original story

    Jun 15, 2015 | TheStreet.com

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 9+ You may proceed to the site by clicking here , however some pages might not work correctly.

    Comment?

  7. Can Cell Therapies Help Save Big Pharma From The Patent Cliff?Read the original story w/Photo

    Jun 11, 2015 | Pharmaceutical Online

    A substantial number of large pharmaceutical companies are facing a "patent cliff", as many blockbuster drugs begin going off-patent. Companies manufacturing generic drugs have already stepped in or are set to enter into markets that have been previously dominated by these blockbusters.

    Comment?

  8. New cholesterol-lowering drugs clear stepRead the original story w/Photo

    Jun 9, 2015 | WYFF-TV Greenville

    A Food and Drug Administration advisory committee this week recommended approval of two experimental new cholesterol-fighting drugs that could be more potent and carry fewer side effects than statins, which are among the most prescribed drugs in the United States. The agency will likely follow the advisory committee's advice when it decides whether to approve the drugs, alirocumab from Sanofi SA and Regeneron Pharmaceuticals Inc., and evolocumab from Amgen Inc., for patients later this summer.

    Comment?

  9. FDA Panel Backs Cholesterol Drug Evolocumab (Repatha) for Patients at High Cardiovascular RiskRead the original story

    Jun 11, 2015 | P&T Community

    The FDA's Endocrinologic and Metabolic Drugs Advisory Committee has recommended approval of the cholesterol-lowering drug evolocumab , but said it should be used only in patients at high risk of cardiovascular disease, according to a Reuters report. Evolocumab is designed to be administered as a subcutaneous injection in biweekly doses of 140 mg or in a monthly dose of 420 mg, with both regimens given on top of statins, if patients can tolerate them.

    Comment?

  10. US experts urge approval of new cholesterol drugRead the original story w/Photo

    Jun 11, 2015 | The Peninsula

    US experts urged regulators Wednesday to approve a second new anti-cholesterol drug, a day after recommending they bring to market the first in a new class of medications to lower the risk of heart attack. The advisory panel to the US Food and Drug Administration voted 11-4 that the benefits of Amgen's drug evolocumab outweighed the risks, and was unanimous in its decision that the drug should be approved.

    Comment?

  11. Amgen Cholesterol Drug Wins Panel Backing for Some PatientsRead the original story

    Jun 10, 2015 | The Washington Post

    Repatha's benefits outweigh its risks for some patients with difficult-to-treat high cholesterol, advisers to the Food and Drug Administration voted 11-4 on Wednesday. They also voted 15-0 that the medicine's benefits outweigh its risks for patients with a rare genetic disorder that causes ultra-high cholesterol levels.

    Comment?

  12. Two new, potent cholesterol-lowering drugs get FDA advisory approvalRead the original story w/Photo

    Jun 10, 2015 | WTVR Richmond

    A Food and Drug Administration advisory committee this week recommended approval of two experimental new cholesterol-fighting drugs that could be more potent and carry fewer side effects than statins, which are among the most prescribed drugs in the United States. The agency will likely follow the advisory committee's advice when it decides whether to approve the drugs, alirocumab from Sanofi SA and Regeneron Pharmaceuticals Inc., and evolocumab from Amgen Inc., for patients later this summer.

    Comment?

  13. FDA panel backs Amgen's cholesterol drug for high-risk patientsRead the original story

    Jun 10, 2015 | Reuters

    An advisory panel to the U.S. Food and Drug Administration recommended approval of Amgen Inc's cholesterol-lowering drug Repatha on Wednesday, but said it should be used only in patients at high risk of cardiovascular disease. The panel voted unanimously to recommend approval of the drug, known also as evolocumab, for patients with homozygous familial hypercholesterolemia , a hereditary disorder characterized by high LDL levels that can cause heart attacks in very young people.

    Comment?

  14. UPDATE 1-FDA panel backs Amgen's cholesterol drug for high-risk patientsRead the original story

    Jun 10, 2015 | Reuters

    An advisory panel to the U.S. Food and Drug Administration recommended approval of Amgen Inc's cholesterol-lowering drug Repatha on Wednesday, but said it should be used only in patients at high risk of cardiovascular disease. The panel voted unanimously to recommend approval of the drug, known also as evolocumab, for patients with homozygous familial hypercholesterolemia , a hereditary disorder characterized by high LDL levels that can cause heart attacks in very young people.

    Comment?

  15. New, Potent Cholesterol-Lowering Drug Gets FDA Advisory ApprovalRead the original story w/Photo

    Jun 10, 2015 | WHO-TV Des Moines

    A Food and Drug Administration advisory committee on Tuesday recommended approval of a new type of experimental cholesterol-fighting drug that could be more potent and carry fewer side effects than statins, which are among the most prescribed drugs in the United States. The agency will likely follow the advisory committee's advice when it decides whether to approve the drug, alirocumab from Sanofi SA and Regeneron Pharmaceuticals Inc., for patients later this summer.

    Comment?

  16. US experts urge approval of another new cholesterol drugRead the original story w/Photo

    Jun 10, 2015 | PhysOrg Weblog

    US experts urged regulators Wednesday to approve a second new anti-cholesterol drug, a day after recommending they bring to market the first in a new class of medications to lower the risk of heart attack. The advisory panel to the US Food and Drug Administration voted 11-4 that the benefits of Amgen's drug evolocumab outweighed the risks, and was unanimous in its decision that the drug should be approved.

    Comment?

  17. Panel Recommends Approval Of New Cholesterol DrugRead the original story w/Photo

    Jun 10, 2015 | WBNS

    A Food and Drug Administration advisory committee on Tuesday recommended approval of a new type of experimental cholesterol-fighting drug that could be more potent and carry fewer side effects than statins, which are among the most prescribed drugs in the United States. The agency will likely follow the advisory committee's advice when it decides whether to approve the drug, alirocumab from Sanofi SA and Regeneron Pharmaceuticals Inc., for patients later this summer.

    Comment?

  18. Next 25 ArticlesRead the original story

    Jun 9, 2015 | Lucianne.com

    Eric Casebolt, the McKinney police officer caught on video forcefully pushing a teenage girl outside a pool party, has resigned, his lawyer, Jane Bishkin, said on Tuesday. Casebolt was on paid administrative leave since the video went viral over the weekend.

    Comment?

  19. FDA Panel Backs Cholesterol Drug but Raises ConcernsRead the original story w/Photo

    Jun 9, 2015 | Wall Street Journal

    A Food and Drug Administration advisory panel recommended that the agency approve the cholesterol-lowering drug Praluent, the first of a wave of such cardiovascular drugs expected to raise billions of dollars in revenue and perhaps alter the treatment of cardiovascular disease. But many panelists said the use of the drug should be limited to certain high-risk groups, such as people with very high cholesterol for genetic reasons because of a condition called familial hypercholesterolemia.

    Comment?

  20. New, potent cholesterol-loweringdrugs get FDA advisory approvalRead the original story

    Jun 9, 2015 | Lucianne.com

    A Food and Drug Administration advisory committee approved two experimental cholesterol-fighting drugs that could be more potent and carry fewer side effects than statins, which are among the most prescribed drugs in the United States. The drugs - alirocumab from Sanofi SA and Regeneron Pharmaceuticals Inc. and evolocumab from Amgen Inc. - would represent the most important new class of cholesterol-lowering medications since the first statin was approved in 1987.

    Comment?